Spirovant Launches State-of-the-Art Laboratory and Headquarters

The facilities are located in the center of Philadelphia’s thriving life sciences corridor Philadelphia, PA, May 17, 2022 – Spirovant Sciences, a gene therapy company developing treatments for inherited respiratory diseases, including cystic fibrosis (CF), announced today the launch of its new state-of-the-art research laboratory and corporate headquarters in Philadelphia. The new research facilities will allow […]

Spirovant Presents Preclinical Data Showing SP-101 Restores CF Transmembrane Conductance Regulator Function at the 2021 North American Cystic Fibrosis Conference

Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021). In oral and poster presentations, […]

Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership

Accomplished Leaders in Gene Therapy Join Team PHILADELPHIA, PA, January 26, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for respiratory diseases including cystic fibrosis, today announced the leasing of its new, expanded headquarters and laboratories in the robust gene and cell therapy epicenter of Philadelphia’s University City in Wexford Science + Technology’s uCity Square at […]

Spirovant CEO Joan Lau Selected EY Entrepreneur of The Year® in Greater Philadelphia

PHILADELPHIA, PA, Oct. 13, 2020 (GLOBE NEWSWIRE) — PHILADELPHIA, PA, October 13, 2020 – Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that its CEO, Joan Lau, PhD, has been selected to receive  the Ernst & Young LLP (EY US) Entrepreneur of The Year 2020 Award in Greater Philadelphia by […]

Spirovant CEO Joan Lau Selected as a Woman of Distinction by Philadelphia Business Journal

Philadelphia, PA, October 7, 2020 — Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that its CEO, Joan Lau, PhD, has been named a  2020 Woman of Distinction by the Philadelphia Business Journal. The Philadelphia Business Journal’s Women of Distinction Awards Program honors women in the business community […]

FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis

PHILADELPHIA, PA, September 24, 2020 – Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis. SPIRO-2101, an inhaled adeno-associated virus […]

Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer

MedImmune R&D veteran delivers 20+ years of experience in respiratory sciences and drug discovery Philadelphia, PA, May 13, 2020 – Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis (CF), today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in […]